Library

X
feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
  • Allogeneic bone marrow transplantation  (1)
  • Hepatitis B  (1)
  • 1
    Electronic Resource
    Electronic Resource
    Apparent decrease and elimination of BCR/ABL mRNA-expressing residual cells in patients with chronic myelogenous leukemia after allogeneic bone marrow transplantation (1991)
    Springer
    Annals of hematology 63 (1991), S. 189-194 
    Details
    ISSN: 1432-0584
    Keywords: Chronic myelogenous leukemia ; Allogeneic bone marrow transplantation ; Minimal residual disease ; BCR/ABL mRNA
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Summary A modified two-step polymerase chain reaction (PCR) was used for the amplification of BCR/ABL mRNA in 16 patients with Philadelphia chromosomepositive (Ph+) chronic myelogenous leukemia (CML) following allogeneic bone marrow transplantation (BMT). At different intervals after BMT, patient cells were assessed for the presence of BCR/ABL mRNA by two subsequent rounds of PCR amplification; this procedure increased the sensitivity for the detection of one Ph+ cell in 104–5 to one cell in 105–6. Eight of 16 patients were negative by two-step PCR 1–39 months after BMT, suggesting an elimination of Ph-positive cells or a decrease below the threshold of detection. Although five patients showed negative results by the one-step PCR only, they were tested positive when nested primers were used, indicating a substantial decrease in the amount of BCR/ABL target mRNA compared with earlier pre- or post-transplant analyses. One patient who was still PCR positive 27 months after BMT became negative 12 months later. Persistence of BCR/ABL mRNA-expressing cells correlated with subsequent clinical relapse only when the transplantation was performed during blast crisis. All patients who underwent transplantation in chronic phase, including those with BCR rearrangement by PCR, are in clinical and hematological remission between 24 and 95 months after BMT. We conclude that aggressive chemotherapy combined with total body irradiation is unable to completely eradicate the malignant clone in all CML patients, and it might be speculated that other mechanisms (e.g., graft versus host reaction [GVHD] or graft versus leukemia effect [GVL]) may effectively eliminate residual leukemic cells.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01703441
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
  • 2
    Electronic Resource
    Electronic Resource
    Solid-phase radioimmunoassay for hepatitis be antigen (HBeAg) (1979)
    Springer
    Journal of molecular medicine 57 (1979), S. 1129-1132 
    Details
    ISSN: 1432-1440
    Keywords: Hepatitis B ; HBsAg ; HBeAg ; Anti-HBe ; Solid-Phase Radioimmunoassay ; Hepatitis B ; HBsAg ; HBeAg ; anti-HBe ; Solid-Phase Radioimmunoassay
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Summary A solid-phase radioimmunoassay was developed for the detection of HBeAg and anti-HBe in sera or serum fractions. HBe/sAg positive sera, partially purified HBeAg, partially purified HBsAg, and HBe/sAg negative sera were polymerized in polyacrylamide and compared for their ability to bind125I-IgG (anti-HBe). Only gels containing HBeAg reacted specifically with the iodinated antibody. The specificity of the binding was confirmed by blocking and inhibition tests using anti-HBe, HBeAg, HBsAg, and negative control sera. The radioimmunoassay allows the specific and quantitative detection of HBeAg and anti-HBe even in the presence of detergents and high salt concentrations.
    Notes: Zusammenfassung Ein Radioimmunoassay wurde entwickelt zum Nachweis von HBeAg und anti-HBe in Serum oder Serumfraktionen. HBe/sAg positives Serum, teilweise gereinigtes HBeAg, teilweise gereinigtes HBsAg und HBe/sAg negatives Kontrollserum wurden in Polyacrylamid polymerisiert und auf ihre Bindungsfähigkeit für125I-IgG (anti-HBe) untersucht. Nur Gele mit immobilisiertem HBeAg reagierten spezifisch mit anti-HBe. Die Spezifität der Bindung wurde gesichert durch Blockierungs-/Inhibitionsteste mit anti-HBe, HBeAg, HBsAg und negativen Kontrollseren. Der Radioimmunoassay ermöglicht den spezifischen und quantitativen Nachweis von HBeAg und anti-HBe, auch in Gegenwart von Detergentien und hohen Salzkonzentrationen.
    Type of Medium: Electronic Resource
    URL: http://dx.doi.org/10.1007/BF01481494
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
    Paper (German National Licenses)
    Fulltext
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...